



VOLUME ONE HUNDRED AND FORTY FIVE

# INTERNATIONAL REVIEW OF NEUROBIOLOGY

Mitochondrial Dysfunction in  
Neurodegeneration and Peripheral  
Neuropathies

Edited by

**PAUL FERNYHOUGH**

*Division of Neurodegenerative Disorders,  
St Boniface Hospital Albrechtsen Research Centre and  
Department of Pharmacology & Therapeutics,  
University of Manitoba, Winnipeg, MB, Canada*

**NIGEL A. CALCUTT**

*Department of Pathology,  
University of California San Diego,  
La Jolla, CA, United States*



**ACADEMIC PRESS**

An imprint of Elsevier

# Contents

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xi</i>
<i>Acknowledgments</i>	<i>xiii</i>
<b>1. Mitochondriopathy: The unifying concept in distal neuropathies?</b>	<b>1</b>
Robert E. Schmidt	
1. Introduction	2
2. Mitochondriopathy in peripheral neuropathy: Overview	3
3. Recent basic science contributions to understanding and treatment of peripheral neuropathy	4
4. Autonomic nervous system: Diabetes and aging in rodents	6
5. Synopses of the chapters	8
References	10
<b>2. Dysfunction of mitochondria: Implications for Alzheimer's disease</b>	<b>13</b>
Benedict C. Albeni	
1. What is Alzheimer's disease?	14
2. Mitochondrial cascade	15
3. Mechanisms of mitochondrial dysfunction	16
4. Mitochondrial medicine in Alzheimer's disease	23
5. Conclusions	24
Acknowledgments	24
References	24
<b>3. HIV in the cART era and the mitochondrial: immune interface in the CNS</b>	<b>29</b>
Jerel Adam Fields and Ronald J. Ellis	
1. Introduction	30
2. HIV proteins and mitochondrial dysfunction in the CNS	38
3. cART and mitochondrial dysfunction in the CNS	48
4. Preventing HIV-induced mitochondrial toxicity	51
5. Conclusion	54
References	55

<b>4. Mitochondrial dysfunction in HIV-induced peripheral neuropathy</b>	<b>67</b>
Ricardo H. Roda and Ahmet Hoke	
1. Introduction	68
2. Mitochondrial abnormalities in HIV peripheral neuropathy	69
3. mtDNA variation and HIV-SN	76
4. Mitochondrial fusion and fission	77
5. Future directions	77
References	78
<b>5. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy</b>	<b>83</b>
Annalisa Trecarichi and Sarah J.L. Flatters	
1. Introduction	84
2. Nature of mitochondrial dysfunction evoked by chemotherapy	90
3. Counteracting mitochondrial dysfunction via pharmacological interventions	102
4. Conclusion	116
References	116
<b>6. Disorders of mitochondrial dynamics in peripheral neuropathy: Clues from hereditary neuropathy and diabetes</b>	<b>127</b>
Amy E. Rumora, Masha G. Savelieff, Stacey A. Sakowski, and Eva L. Feldman	
1. Introduction	128
2. Mitochondrial dynamics	130
3. Mitochondrial dynamics in disease	139
4. Regulation of mitochondrial dynamics by glucose	151
5. Regulation of mitochondrial dynamics by dyslipidemia	153
6. Conclusions	161
Acknowledgments	162
References	162
<b>7. Role of mitochondria in diabetic peripheral neuropathy: Influencing the NAD<sup>+</sup>-dependent SIRT1–PGC-1<math>\alpha</math>–TFAM pathway</b>	<b>177</b>
Krish Chandrasekaran, Muragundla Anjaneyulu, Jounghil Choi, Pranith Kumar, Mohammad Salimian, Cheng-Ying Ho, and James W. Russell	
1. Introduction	178
2. Mitochondrial hypothesis of diabetic peripheral neuropathy	179

3.	Control of mitochondrial biogenesis: The SIRT1–PGC-1 $\alpha$ TFAM axis	181
4.	PGC1- $\alpha$ in neuropathy: Effect on diabetes and lipid metabolism	182
5.	Neuropathy is more severe in diabetic PGC-1 $\alpha$ knockout mice	184
6.	Effect of PGC-1 $\alpha$ knockout on mitochondrial function in diabetic neuropathy	185
7.	TFAM and mtDNA: Transcription, replication, and protection	186
8.	Overexpression of human TFAM protects against DPN	187
9.	Administration of the mGluR 2/3 agonist, LY379268, protects against DPN	189
10.	Role of NAD <sup>+</sup> analogues in DPN	194
11.	The choice of NAD <sup>+</sup> precursor is critical	195
12.	SIRT1 and DPN	197
13.	Conclusion	199
	Acknowledgments	199
	References	199
<b>8.</b>	<b>Dichloroacetate-induced peripheral neuropathy</b>	<b>211</b>
	Peter W. Stacpoole, Christopher J. Martyniuk, Margaret O. James, and Nigel A. Calcutt	
1.	Introduction	212
2.	Dichloroacetate pharmacokinetics and metabolism	213
3.	Dichloroacetate pharmacodynamics and clinical utility	214
4.	Dichloroacetate toxicity and neuropathy	218
5.	Future avenues of potential research	228
6.	Summary	232
	References	233
	Further reading	238